The aim is to determine important indicators for selecting innovative anticancer drugs in China through expert consensus.
Conducted a Delphi study with expert panels including patient representatives.
Collected ratings on candidate indicators from participants.
Gathered feedback on interview guides and questionnaires.
Identified priority indicators rated by participants.
Received valuable input regarding lived experiences from patient representatives.
Abstract
Patient representatives participated in the first-round expert panel, where they rated candidate indicators, shared their lived experiences, and provided feedback on the interview guides and questionnaires.